Breaking down the evidence for bevacizumab in ovarian cancer.
Editorial Article
Overview
abstract
Bevacizumab has been FDA-approved for use in combination with single-agent chemotherapy for platinum-resistant ovarian cancer; however, its optimal role remains unclear. In this editorial, the timing, efficacy, safety, and rationale for use of bevacizumab in ovarian cancer are discussed.
